Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Naxitamab + GM-CSF: Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles. Isotretinoin: Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles.”In the company’s words, NCT06047535 on ClinicalTrials.gov
- Tested for
- Neuroblastoma
- Main trialPhase 4
- “This is a single-arm, multicenter clinical trial conducted in patients ≥ 12 months of age with high-risk neuroblastoma in first complete response. 62 patients will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin. In line with post-consolidation maintenance treatment of high-risk neuroblastoma, this trial will include patients with high-risk neuroblastoma in first complete response. Patients must have completed a multimodal frontline regimen (induction and consolidation) and have achieved complete response (positive bone marrow minimal residual disease as assessed…”In the company’s words, NCT06047535 on ClinicalTrials.gov
Other drugs for Neuroblastoma
- EB-DTNB-NKBeijing Biotech · Phase 1/2
- APG-115Ascentage Pharma Group Inc. · Phase 1/2
- LisaftoclaxAscentage Pharma Group Inc. · Phase 1/2
- EntrectinibRoche · Phase 1/2
- Zilovertamab vedotinMerck & Co. · Phase 1/2
- Allogenic NK cellsMarzieh Ebrahimi · Phase 1
Coming up1
- 15 Jun 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | 15 Jun 2027 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | |
| Phase 2Authorised | not given | To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma. | |
| Phase 2Authorised | not given | A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026